Creon is an enzyme that helps in digestion.
Release form and composition
Drug form of Creon - solid gelatin enteric capsules containing minimicrospheres of light brown color:
- Kreon 10000: size No. 2 with a transparent colorless case and an opaque brown lid (20 or 50 each in plastic bottles, 1 bottle in a cardboard box; 10 each in blisters, 2 blisters in a cardboard box; 25 each. in blisters, 2 or 4 blisters in a carton box);
- Creon 25000: size 0, with a transparent colorless case and an opaque orange-brown lid (20, 50 or 100 each in plastic bottles, 1 bottle in a cardboard box; 10 each in a blister pack, 2 blisters in a cardboard box ; 25 pieces in blisters, 2 or 4 blisters in a carton box);
- Kreon 40000: size №00, with a transparent colorless case and an opaque brown lid (20, 50 or 100 pieces in plastic bottles, 1 bottle in a cardboard box).
The active ingredient of the drug is pancreatin, which contains pancreatic enzymes (amylase, lipase and protease). Their content in different forms of release:
- Creon 10000: pancreatin - 150 mg (protease - 600 U of EF, amylase - 8000 U of EF, lipase - 10,000 U of EF);
- Creon 25000: pancreatin - 300 mg (protease - 1000 U of EF, amylase - 18000 U of EF, lipase - 25000 U of EF);
- Creon 40000: pancreatin - 400 mg (protease - 1600 U of EF, amylase - 25000 U of EF, lipase - 40000 U of EF).
Auxiliary components: hypromellose phthalate, cetyl alcohol, dimethicone 1000, macrogol 4000 and triethyl citrate.
The composition of the shell: gelatin, titanium dioxide (E171), sodium lauryl sulfate and dye (CREON 10,000 and 40,000 - ferrous oxide red (E172), ferrous oxide yellow (E172) and ferric oxide black (E172); Creon 25000 - ferrous oxide yellow (E172 ) and iron oxide red (E172)).
Indications for use
Replacement therapy for exocrine pancreatic insufficiency, which developed as a result of the following conditions:
- Chronic pancreatitis;
- Pancreas cancer;
- Cystic fibrosis;
- Shwachman-Diamond Syndrome;
- Ductal obstruction due to neoplasm (for example, obstruction of the common bile duct or pancreatic duct);
- Reduced enzyme-forming function of the gastrointestinal tract in elderly patients.
Symptomatic therapy of disorders of the digestive processes in the following cases:
- Biliary obstruction;
- Duodeno- and gastrostasis;
- Total gastrectomy;
- Partial resection of the stomach (Billroth-I / II);
- Cirrhosis of the liver;
- Cholestatic hepatitis;
- Pathology of the terminal part of the small intestine;
- Conditions after cholecystectomy;
- Excessive bacterial growth in the small intestine.
- Exacerbation of chronic pancreatitis;
- Acute pancreatitis;
- Hypersensitivity to pancreatin of porcine origin or auxiliary components of the drug.
During pregnancy and lactation, Creon can be prescribed after a careful assessment of the ratio of the expected positive effect for the woman and the possible risks to the baby.
Dosing and Administration
The drug is intended for oral administration. 1/2 or 1/3 of a single dose is recommended to be taken at the beginning of a meal, the rest - with meals. Capsules should be swallowed whole, without chewing, drinking plenty of water. Patients who have difficulty swallowing (for example, young children and the elderly) can open the capsules and take the mini-microspheres contained in them with liquid (with a pH of less than 5) or add to liquid foods that do not require chewing. Any mixture of the drug with liquid or food can not be stored, it must be taken immediately after preparation.
Doses in each case are determined individually, taking into account the severity of the course of the disease and the composition of the diet.
The initial dose of lipase in cystic fibrosis is as follows: for children up to 4 years old - 1000 U of EF for each meal, for children over 4 years of age - 500 U of EF for every meal. In this case, when selecting a dose, the results of steatorrhea control are also taken into account. In most cases, the dose of lipase does not exceed 10,000 U of EF / kg / day.
In other conditions that are accompanied by exocrine pancreatic insufficiency, the dose is determined depending on the degree of insufficiency of the digestive system, taking into account the fat content in food. Doses of lipase: at the main meal (breakfast, lunch or dinner) - 20000-75000 AU EF, for light meals - 5000-25000 AU of EF.
The average initial dose of lipase at the main meal is 10,000-25,000 IU EF. However, to minimize steatorrhea and maintain good nutritional status, higher doses may be needed. According to clinical practice, the patient should receive at least 20000-50000 U of EF lipase with food.
When taking Creon, patients often complain of abdominal pain. Changes in stool, stomach discomfort, nausea and / or vomiting, diarrhea or constipation are rarely observed.
In some cases, possible hypersensitivity reactions.
In patients with cystic fibrosis, receiving the drug in high doses, there is a possibility of the development of colitis, stricture of the ileum and cecum.
When taking excessively high doses, hyperuricemia and hyperuricuria are possible. In this case, discontinue the drug and prescribe symptomatic therapy.
During treatment, it is important to ensure adequate fluid intake, because its absence can lead to increased constipation.
Chewing, grinding or adding minimicrospheres to foods with a pH of more than 5.5 leads to the destruction of their shell, which protects against the action of gastric juice.
Children with cystic fibrosis who take Creon 25000 for a long time should be under constant medical supervision.
To exclude colon lesions, as a precautionary measure in patients with cystic fibrosis, it is recommended to control all unusual symptoms or changes in the abdominal cavity, especially in patients taking more than 10,000 IU of lipase / kg per day.
The drug Creon can be taken by patients who practice Judaism and Islam.
Negative impact on the reaction rate and ability to concentrate the attention of the drug does not have.
Clinically significant interaction of Creon with other drugs has not been revealed until today.
Terms and conditions of storage
Keep out of reach of children at temperature: CREON 10,000 and 25,000 in blisters - up to 20 ° C, CREON 10,000 and 25,000 in bottles - up to 25 ° C, CREON 40000 - up to 30 ° C in tightly closed packaging.
- Creon 10,000 and 25,000 in blisters, Creon 10,000 in vials - 2 years;
- Creon 25,000 and 40,000 in bottles - 3 years.
After opening the bottle, the shelf life is 6 months.